MSLE Satellos Bioscience Inc.
$6.59▼ -4.22%
Healthcare
Other
Volume 39.8K
Avg Volume (10D) 34.2K
Key Metrics & Fundamentals
Market Cap
$139.82M
P/E Ratio
–
Div Yield
0.00%
52W Range
5.30 - 13.40
% vs 50 MA
-18.90%
% vs 200 MA
-19.01%
RSI-14
40.4
MACD Histogram
+0.0300
Beta (1Y vs SPY)
1.43
Free Cash Flow
-$8.03M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$12.08M
COGS
–
Operating Exp
$12.17M
Operating Income
-$12.17M
EBIT
-$12.17M
Pretax Income
-$11.67M
Net Income
-$11.72M
EPS (Diluted)
-0.56
Price & Volume History
Loading chart…
Recent News
Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience
GlobeNewswire · Oct 27, 2026 7:00 AM ET
Satellos to Participate in Upcoming Investor Conferences
GlobeNewswire · Oct 21, 2026 7:00 AM ET
Satellos Bioscience Granted Composition of Matter Patent for Forazapadin by USPTO
MT Newswires · Oct 5, 2026 9:34 AM ET
Satellos Granted Composition of Matter Patent for Forazapadin
GlobeNewswire · Oct 5, 2026 7:00 AM ET
Satellos Bioscience Completes Enrollment in Phase 2 Basecamp Trial
MT Newswires · Sep 30, 2026 2:00 PM ET
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
GlobeNewswire · Sep 30, 2026 7:00 AM ET
Satellos Receives FDA Clearance For FSHD Investigational New Drug Application
MT Newswires · Sep 24, 2026 12:32 PM ET
Satellos Receives FDA Clearance to Study Forazapadin in FSHD
InvestorsHub · Sep 24, 2026 9:59 AM ET
Satellos stock jumps after FDA clears FSHD trial for forazapadin
Investing.com · Sep 24, 2026 9:54 AM ET
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
GlobeNewswire · Sep 24, 2026 7:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See MSLE's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.